Aromatase Inhibition Therapy의 임상 단계는?

Aromatase Inhibition Therapy의 현재 단계는 Phase 2입니다.

비슷한 프로그램과 어떻게 비교하나요?

바이오모아 (BioMoa) 비교 페이지에서 PK/PD, 독성, 임상 효능 지표를 나란히 볼 수 있습니다. 동일 타깃·모달리티 프리셋을 함께 참고하세요.

Aromatase Inhibition Therapy의 임상 단계는?

Aromatase Inhibition Therapy의 현재 단계는 Phase 2입니다.

비슷한 프로그램과 어떻게 비교하나요?

바이오모아 (BioMoa) 비교 페이지에서 PK/PD, 독성, 임상 효능 지표를 나란히 볼 수 있습니다. 동일 타깃·모달리티 프리셋을 함께 참고하세요.

← 프로그램 목록

Phase 2Active

Aromatase Inhibition Therapy

Genentech

비교

Aromatase Inhibition Therapy(Genentech, Inc.)은 HER2 표적 치료제로, Male Breast Cancer; Stage II Breast Cancer 영역에서 개발·상용화 중입니다. 작용기전: Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 100% (ClinicalTrials.gov NCT01823835). 차별점: Novel Binders Identified Using DNA-Encoded Chemical Library Screening.

개요

임상 2026년 7월 12일 (1일 전)PK/독성 2026년 7월 12일 (1일 전)

타깃

HER2

적응증

Male Breast Cancer; Stage II Breast Cancer

상태

Active

Technology

구조모아 · Exatecan/DXd (TOP1)

Platform

Bispecific Estrogen Receptor α Degraders Incorporating Novel Bin

Payload

deruxtecan in TROP2-expressing low-grade serous ov

Linker

linker positioning, and binding elements are determined directly from the screen

Differentiator

Novel Binders Identified Using DNA-Encoded Chemical Library Screening

Mechanism of Action

Mechanism

Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor

Immune activation

macrophage polarisation, T-helper cell bias, and dysregulated natural killer cell cytotoxicity

Cytotoxicity

apoptosis-inducing effects of naphthoquinone-triazole derivatives for potential anti-breast cancer agents: In vitro and molecular

Biomarker

biomarkers, nutraceutical intervention for elevated prostate-specific antigen

Resistance

resistance to endocrine therapy by suppressing hyperinsulinemia-driven growth signaling, remodeling adipokine and inflammatory networ

임상시험 & 결과

차트 로드 중…

임상 한눈에 보기

62건의 ClinicalTrials.gov 임상 기록
Phase·Status 요약은 enrollment 상위 표본 기준입니다
임상시험 탭에서 enrollment 상위 목록을 불러올 수 있습니다
Phase: Phase 4 · Phase 3 · Phase 1
Status: Completed · Unknown status · Recruiting
주요 endpoint: Disease free survival in association with tested genotypes (whole genome scan) · Overall survival in association with tested genotypes Quality of life in association with tested genotypes Health economy in the use of aromatase inhibitors Identification of genetic susceptibility markers for hormonal receptor positive breast cancer · Total treatment duration and cycle for Palbociclib · Assessment on dose modification of Palbociclib as first line of therapy in BC patients in real-world setting. · disease free survival in premenopausal patients
등록된 결과: ORR 100%
핵심: This study is a multi-institution, Phase Ia/Ib/IIa open-label, dose-finding, safety, pharmacokinetics (PK), and proof-of…

임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.

수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.

참고문헌

DIM and PSA Reduction: Blocking Aromatization for Prostate Health: A Case Report. — PubMed (2026)
Use of Pharmacokinetic and Pharmacodynamic Data to Develop the CDK4/6 Inhibitor Ribociclib for Patients with Advanced Breast Cancer. — PubMed (2024)
A Review on the Use of Letrozole in Female and Male Infertility. — PubMed (2022)
Characterization of Cytosolic Glutathione S -Transferases Involved in the Metabolism of the Aromatase Inhibitor, Exemestane. — PubMed (2021)

자주 묻는 질문

Aromatase Inhibition Therapy은 어떤 치료제인가요?: Aromatase Inhibition Therapy(Genentech, Inc.)은 HER2 표적 항체로, Male Breast Cancer; Stage II Breast Cancer 영역에서 개발·상용화 중입니다. 데이터는 바이오모아 (BioMoa)에서 ClinicalTrials.gov·openFDA·PubMed 기반으로 정리합니다.
Aromatase Inhibition Therapy의 임상 단계는?: Aromatase Inhibition Therapy의 현재 단계는 Phase 2입니다.
비슷한 프로그램과 어떻게 비교하나요?: 바이오모아 (BioMoa) 비교 페이지에서 PK/PD, 독성, 임상 효능 지표를 나란히 볼 수 있습니다. 동일 타깃·모달리티 프리셋을 함께 참고하세요.

갱신 기록 없음 · 14일 주기 · 방문 16 / 568

← 프로그램 목록

Phase 2Active

Aromatase Inhibition Therapy

Genentech

비교

개요

임상 2026년 7월 12일 (1일 전)PK/독성 2026년 7월 12일 (1일 전)

타깃

HER2

적응증

Male Breast Cancer; Stage II Breast Cancer

상태

Active

Technology

구조모아 · Exatecan/DXd (TOP1)

Platform

Bispecific Estrogen Receptor α Degraders Incorporating Novel Bin

Payload

deruxtecan in TROP2-expressing low-grade serous ov

Linker

linker positioning, and binding elements are determined directly from the screen

Differentiator

Novel Binders Identified Using DNA-Encoded Chemical Library Screening

Mechanism of Action

Mechanism

Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor

Immune activation

macrophage polarisation, T-helper cell bias, and dysregulated natural killer cell cytotoxicity

Cytotoxicity

apoptosis-inducing effects of naphthoquinone-triazole derivatives for potential anti-breast cancer agents: In vitro and molecular

Biomarker

biomarkers, nutraceutical intervention for elevated prostate-specific antigen

Resistance

resistance to endocrine therapy by suppressing hyperinsulinemia-driven growth signaling, remodeling adipokine and inflammatory networ

임상시험 & 결과

차트 로드 중…

임상 한눈에 보기

62건의 ClinicalTrials.gov 임상 기록
Phase·Status 요약은 enrollment 상위 표본 기준입니다
임상시험 탭에서 enrollment 상위 목록을 불러올 수 있습니다
Phase: Phase 4 · Phase 3 · Phase 1
Status: Completed · Unknown status · Recruiting
주요 endpoint: Disease free survival in association with tested genotypes (whole genome scan) · Overall survival in association with tested genotypes Quality of life in association with tested genotypes Health economy in the use of aromatase inhibitors Identification of genetic susceptibility markers for hormonal receptor positive breast cancer · Total treatment duration and cycle for Palbociclib · Assessment on dose modification of Palbociclib as first line of therapy in BC patients in real-world setting. · disease free survival in premenopausal patients
등록된 결과: ORR 100%
핵심: This study is a multi-institution, Phase Ia/Ib/IIa open-label, dose-finding, safety, pharmacokinetics (PK), and proof-of…

임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.

수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.

참고문헌

DIM and PSA Reduction: Blocking Aromatization for Prostate Health: A Case Report. — PubMed (2026)
Use of Pharmacokinetic and Pharmacodynamic Data to Develop the CDK4/6 Inhibitor Ribociclib for Patients with Advanced Breast Cancer. — PubMed (2024)
A Review on the Use of Letrozole in Female and Male Infertility. — PubMed (2022)
Characterization of Cytosolic Glutathione S -Transferases Involved in the Metabolism of the Aromatase Inhibitor, Exemestane. — PubMed (2021)

자주 묻는 질문

Aromatase Inhibition Therapy은 어떤 치료제인가요?: Aromatase Inhibition Therapy(Genentech, Inc.)은 HER2 표적 항체로, Male Breast Cancer; Stage II Breast Cancer 영역에서 개발·상용화 중입니다. 데이터는 바이오모아 (BioMoa)에서 ClinicalTrials.gov·openFDA·PubMed 기반으로 정리합니다.
Aromatase Inhibition Therapy의 임상 단계는?: Aromatase Inhibition Therapy의 현재 단계는 Phase 2입니다.
비슷한 프로그램과 어떻게 비교하나요?: 바이오모아 (BioMoa) 비교 페이지에서 PK/PD, 독성, 임상 효능 지표를 나란히 볼 수 있습니다. 동일 타깃·모달리티 프리셋을 함께 참고하세요.

ADC Antibody CGT 🫁 폐암 (NSCLC)🎗️ HER2+ 유방암 🦴 다발성 골수종 👁️ 황반변성·망막 🛡️ 자가면역·염증성 🧴 건선 질병 전체 →

← 프로그램 목록

Phase 2Active

Aromatase Inhibition Therapy

Genentech

비교

개요

임상 2026년 7월 12일 (1일 전)PK/독성 2026년 7월 12일 (1일 전)

타깃

HER2

적응증

Male Breast Cancer; Stage II Breast Cancer

상태

Active

Technology

구조모아 · Exatecan/DXd (TOP1)

Platform

Bispecific Estrogen Receptor α Degraders Incorporating Novel Bin

Payload

deruxtecan in TROP2-expressing low-grade serous ov

Linker

linker positioning, and binding elements are determined directly from the screen

Differentiator

Novel Binders Identified Using DNA-Encoded Chemical Library Screening

Mechanism of Action

Mechanism

Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor

Immune activation

macrophage polarisation, T-helper cell bias, and dysregulated natural killer cell cytotoxicity

Cytotoxicity

apoptosis-inducing effects of naphthoquinone-triazole derivatives for potential anti-breast cancer agents: In vitro and molecular

Biomarker

biomarkers, nutraceutical intervention for elevated prostate-specific antigen

Resistance

resistance to endocrine therapy by suppressing hyperinsulinemia-driven growth signaling, remodeling adipokine and inflammatory networ

임상시험 & 결과

차트 로드 중…

임상 한눈에 보기

62건의 ClinicalTrials.gov 임상 기록
Phase·Status 요약은 enrollment 상위 표본 기준입니다
임상시험 탭에서 enrollment 상위 목록을 불러올 수 있습니다
Phase: Phase 4 · Phase 3 · Phase 1
Status: Completed · Unknown status · Recruiting
주요 endpoint: Disease free survival in association with tested genotypes (whole genome scan) · Overall survival in association with tested genotypes Quality of life in association with tested genotypes Health economy in the use of aromatase inhibitors Identification of genetic susceptibility markers for hormonal receptor positive breast cancer · Total treatment duration and cycle for Palbociclib · Assessment on dose modification of Palbociclib as first line of therapy in BC patients in real-world setting. · disease free survival in premenopausal patients
등록된 결과: ORR 100%
핵심: This study is a multi-institution, Phase Ia/Ib/IIa open-label, dose-finding, safety, pharmacokinetics (PK), and proof-of…

임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.

수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.

참고문헌

DIM and PSA Reduction: Blocking Aromatization for Prostate Health: A Case Report. — PubMed (2026)
Use of Pharmacokinetic and Pharmacodynamic Data to Develop the CDK4/6 Inhibitor Ribociclib for Patients with Advanced Breast Cancer. — PubMed (2024)
A Review on the Use of Letrozole in Female and Male Infertility. — PubMed (2022)
Characterization of Cytosolic Glutathione S -Transferases Involved in the Metabolism of the Aromatase Inhibitor, Exemestane. — PubMed (2021)

자주 묻는 질문

Aromatase Inhibition Therapy은 어떤 치료제인가요?: Aromatase Inhibition Therapy(Genentech, Inc.)은 HER2 표적 항체로, Male Breast Cancer; Stage II Breast Cancer 영역에서 개발·상용화 중입니다. 데이터는 바이오모아 (BioMoa)에서 ClinicalTrials.gov·openFDA·PubMed 기반으로 정리합니다.
Aromatase Inhibition Therapy의 임상 단계는?: Aromatase Inhibition Therapy의 현재 단계는 Phase 2입니다.
비슷한 프로그램과 어떻게 비교하나요?: 바이오모아 (BioMoa) 비교 페이지에서 PK/PD, 독성, 임상 효능 지표를 나란히 볼 수 있습니다. 동일 타깃·모달리티 프리셋을 함께 참고하세요.

갱신 기록 없음 · 14일 주기 · 방문 16 / 568